NCT04734730View on ClinicalTrials.gov

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

August 23, 2027

Study Completion Date

August 23, 2027

Conditions
Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Bicalutamide

Given PO

DRUG

Degarelix

Given SC

DRUG

Goserelin Acetate

Given SC

DRUG

Leuprolide Acetate

Given IM

DRUG

Prednisone

Given PO

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Talazoparib

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER